HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer

Abstract Background The C797S mutation is one of the most common mechanisms of acquired resistance to third generation EGFR TKIs, yet no approved therapies have been available to target it. Here we developed a novel selective EGFR C797S inhibitor, HS-10375, and report the results of pre-clinical res...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianhua Zhan, Jinhui Xue, Lin Wu, Zhiye Zhang, Qiming Wang, Yuxiang Ma, Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Wenfeng Fang, Yang Zhang, Qianwen Liu, Wen Xu, Yan Yang, Zhenming Chen, Baili Song, Danni Sun, Xia Sun, Peng Gao, Hongyun Zhao, Li Zhang
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Journal of Translational Medicine
Subjects:
EGFR TKI
Non-small cell lung cancer
HS-10375
C797S mutation
Targeted therapy
Online Access:https://doi.org/10.1186/s12967-025-06613-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06613-0

Similar Items